Consequently, we showed that the CLA-induced hepatic triglyceride accumulation can be rescued by small-molecule drugs targeting either PPARα or REV-ERBα with the modified circadian clock program; this may be an alternative strategy to manage the associated metabolic disorders. The gene discussed is NR1D1; the disease is Other metabolic disease.